High cholesterol lab work: beyond LDL — what ApoB and Lp(a) actually tell you
Anchor biomarkers: LDL-C, HDL, ApoB, Lp(a), triglycerides
TL;DR
- •LDL-C is the legacy headline, but ApoB is the better risk number. ApoB counts every atherogenic particle directly; LDL-C estimates mass.
- •Lp(a) is genetic, mostly unmoved by diet/lifestyle, and should be tested once in every adult. Elevated Lp(a) is an independent cardiovascular risk that standard cholesterol panels miss.
- •Two patients with the same LDL can have entirely different cardiovascular risk. Particle number, ApoB, Lp(a), triglyceride/HDL ratio, and inflammation tell the real story.
What each marker tells you
| Marker | Reference range | What it means |
|---|---|---|
| Total cholesterol | < 200 mg/dL | A summary number. Largely superseded by component analysis. |
| LDL-C ("bad" cholesterol) | < 100 mg/dL optimal · < 70 high-risk goal | The traditional risk anchor. Estimated, not measured directly, in most panels. |
| HDL ("good" cholesterol) | > 40 mg/dL (men) / > 50 (women) | Protective; involved in reverse cholesterol transport. |
| Triglycerides | < 100 mg/dL optimal · ≥ 150 elevated | Metabolic marker that rises with insulin resistance. |
| Non-HDL cholesterol | < 130 mg/dL optimal | Total minus HDL — captures all atherogenic particles. Better than LDL alone. |
| ApoB | < 90 mg/dL general · < 80 high-risk goal | The most precise atherogenic particle count. Each LDL, VLDL, IDL particle carries one ApoB. |
| Lp(a) | < 30 mg/dL (or < 75 nmol/L) | Genetic risk marker. Largely fixed for life. Elevated levels = 2–3x cardiovascular risk independent of LDL. |
| ApoA-1 | > 120 mg/dL (men) / > 140 (women) | The protein on HDL particles. Functional HDL marker. |
| hs-CRP | < 1.0 mg/L optimal | Inflammation marker. Cardiovascular events tend to cluster around inflammation + ApoB. |
| Lipoprotein NMR / particle counts | varies | Advanced lipid panel — counts particles directly. Less universal but informative. |
Three real patterns Phi has seen
Example patterns · synthetic data drawn from Phi's scenario library. Not real patient records.
Pattern 1 — "LDL looks fine, ApoB is elevated."
LDL-C 95 (in range). HDL 52. Triglycerides 145. Non-HDL 128. ApoB 105 (elevated). Lp(a) 18 (normal). hs-CRP 2.4. The patient is reassured: "Your cholesterol is fine." The reality: ApoB tells us there are *more* atherogenic particles circulating than the LDL number suggests — typical of insulin resistance where LDL particles are smaller and more numerous. Cardiovascular risk is higher than a single LDL reading would imply.
Example pattern · synthetic data
Pattern 2 — "Normal LDL, elevated Lp(a)."
LDL-C 110. HDL 58. Triglycerides 92. ApoB 88. **Lp(a) 145 (very elevated)**. hs-CRP 0.8. The patient's standard lipid panel is unremarkable, and they're told nothing further. The Phi read: Lp(a) at this level confers roughly 2.5x cardiovascular risk independent of LDL — a finding that should change family screening (Lp(a) is genetic), aggressive LDL targets (often pushing LDL to < 70 with statin), and cardiology referral discussions. About 20% of the population has elevated Lp(a) and most don't know it because it's not in routine panels.
Example pattern · synthetic data
Pattern 3 — Six months on statin, with the right targets.
LDL-C 68 (was 152). HDL 54. Triglycerides 88. ApoB 65 (was 130). Lp(a) 22 (genetic, didn't change). hs-CRP 0.6. The patient is on rosuvastatin 10 mg, eating Mediterranean-pattern, walking after meals. The numbers reflect not just a statin response but a metabolic improvement (triglycerides moved with lifestyle). Both interventions show up in the pattern.
Example pattern · synthetic data
Questions to bring to your doctor
- Has my Lp(a) been measured? It should be checked at least once in every adult.
- Can we add ApoB to my next lipid panel? It's a more precise risk marker than LDL alone.
- What's my non-HDL cholesterol, and is it moving in the right direction?
- Given my risk profile, what's my actual LDL target — < 100, < 70, or lower?
- Have we measured hs-CRP to assess inflammatory contribution?
- If I have elevated Lp(a), should my immediate family be screened?
- What's the role of lifestyle (diet, exercise, weight) vs medication in my specific situation?
- If I'm on a statin and my LDL is at target, why might I still want to push lower on ApoB?
What Phi adds beyond a single number
The cholesterol panel is more nuanced than "LDL high / LDL low." Phi reads LDL + HDL + triglycerides + ApoB + Lp(a) + inflammation markers together, against your own historical trajectory, and against the cardiovascular-risk math that actually applies to your context. The integrated picture tells you whether your "borderline" LDL is benign or hiding ApoB elevation, whether genetic Lp(a) is silently raising your risk, and whether your interventions are moving the markers that matter most.
Upload your most recent lab report. Phi will pull out every cholesterol-relevant marker, compare them against optimal (not just reference) ranges, flag the pattern, and tell you what to ask at your next appointment.
Frequently asked questions
Should I worry about high cholesterol if I feel fine?
Cardiovascular disease is asymptomatic for years before clinical events. The lipid panel is a forward-looking risk indicator, not a current-symptom indicator. Most patients who have heart attacks felt fine the week before.
Is dietary cholesterol the same as blood cholesterol?
No. The 1970s narrative that dietary cholesterol drove blood cholesterol turned out to be too simple. Saturated fat, refined carbohydrates, and trans fats influence lipid numbers more than dietary cholesterol does. Eggs, once vilified, are now generally accepted as neutral for most people.
Can lifestyle change actually lower LDL meaningfully?
Yes, but with limits. Most patients see 10–20% LDL reduction with significant dietary and exercise change. Patients with familial hypercholesterolemia or strongly genetic patterns often need medication regardless. Lifestyle still moves ApoB, triglycerides, HDL, and inflammation favorably.
What's the actual difference between ApoB and LDL-C?
LDL-C is a calculated estimate of the cholesterol mass within LDL particles. ApoB counts the number of atherogenic particles directly (one ApoB per LDL, VLDL, or IDL particle). When LDL particles are small and dense (common in insulin resistance), the same LDL-C number can represent many more particles — ApoB catches that.
My doctor doesn't think I need a statin. Should I push for one?
The decision depends on your 10-year cardiovascular risk score, family history, Lp(a), ApoB, inflammation, and personal preferences. Modern guidelines have shifted to lower LDL targets for many patients. It's a conversation worth having, ideally with ApoB and Lp(a) on the table.
Is Lp(a) really that important?
Yes — and it's underordered. About 20% of people have elevated Lp(a). It carries 2–3x cardiovascular risk independent of LDL. Knowing your number changes risk math, family screening, and treatment intensity. It should be measured at least once in every adult.
Can I lower Lp(a)?
Diet and lifestyle have minimal effect. Niacin and PCSK9 inhibitors lower it modestly. Several Lp(a)-specific drugs are in late-stage trials. For now, knowing your Lp(a) mostly informs how aggressively to manage LDL/ApoB — but treatment options are likely to expand significantly in the next several years.
What about CAC (coronary artery calcium) scoring?
CAC is a CT scan that measures the calcified plaque already deposited in your coronaries. A score of 0 is reassuring; a score > 100 typically warrants aggressive cardiovascular risk management. It's complementary to lipid panels, not a substitute. Many cardiologists recommend CAC for adults 40–70 with intermediate cardiovascular risk.
References
All citations verified against PubMed / publisher of record 2026-05-25.
- 1.Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 73(24):e285-e350. — Current US standard for LDL targets, statin indications, ApoB and Lp(a) discussion, risk-stratification framing. Co-published Circulation 139:e1082-e1143.PubMed →DOI →
- 2.Kronenberg F, Mora S, Stroes ESG, et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 43(39):3925-3946. — Current standard for Lp(a) clinical guidance: causal-and-continuous association with ASCVD; recommendation to test Lp(a) at least once in every adult; basis for the "elevated Lp(a) ~ 2–3x CV risk independent of LDL" framing.PubMed →DOI →
- 3.Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina MJ, Catapano AL, Ference BA. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 4(12):1287-1295. — Foundational review of why ApoB outperforms LDL-C as an atherogenic-risk marker, particularly in patients with discordant LDL-C / ApoB phenotypes.PubMed →DOI →
- 4.Cannon CP, Blazing MA, Giugliano RP, et al. (IMPROVE-IT Investigators). (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 372(25):2387-2397. — IMPROVE-IT: ezetimibe added to statin reduced major cardiovascular events; supports lower-the-better LDL targets.PubMed →DOI →
- 5.Bhatt DL, Steg PG, Miller M, et al. (REDUCE-IT Investigators). (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 380(1):11-22. — REDUCE-IT: prescription-strength icosapent ethyl reduced major cardiovascular events in statin-treated patients with elevated triglycerides.PubMed →DOI →
- 6.Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 376(18):1713-1722. — FOURIER: PCSK9 inhibitor evolocumab on background statin lowered LDL to median 30 mg/dL and reduced major cardiovascular events. Basis for the PCSK9-inhibitor mention.PubMed →DOI →
Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab. All citations verified vs PubMed / publisher of record 2026-05-26.
By Steve Pinedo
Co-founder, Phi Longevity
Last updated: 2026-05-26
Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi →